Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1363 results for social care

  1. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

  2. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

  3. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  4. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

  5. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

  6. Structured clinical management interventions in probation service providers:- What is the effectiveness of structured clinical (case) management in improving mental health outcomes using interventions within probation service providers?

    both CRCs and the NPS. The comparison should be against standard CRC and NPS care. The trial should consider both clinical outcomes and...

  7. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

  8. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

  9. Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]

    Discontinued Reference number: GID-TA10199

  10. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  11. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

  12. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  13. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.

  14. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    for vulnerable groups.In the committee's experience, professionals such as care workers and health visitors, and the public, are...